Movement and Fitness Trackers in Determining Performance Status
Precision Performance Status Assessment in Early Phase Clinical Trials
Sponsor: National Cancer Institute (NCI)
Terminated
Slow accrual
Other terminated trials from National Cancer Institute (NCI)
Other Malignant Neoplasm trials with similar outcome
A NA clinical study on Malignant Neoplasm, this trial is terminated or withdrawn. The trial is conducted by National Cancer Institute (NCI) and has accumulated 10 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Oct 2025 — Present [monthly]
Terminated NA
-
Apr 2025 — Oct 2025 [monthly]
Terminated NA
Status: Recruiting → Terminated
-
Sep 2024 — Apr 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Apr 2024 — Jul 2024 [monthly]
Recruiting NA
▶ Show 5 earlier versions
-
Mar 2023 — Apr 2024 [monthly]
Recruiting NA
-
Sep 2022 — Mar 2023 [monthly]
Recruiting NA
-
May 2021 — Sep 2022 [monthly]
Recruiting NA
-
Jan 2021 — May 2021 [monthly]
Recruiting NA
-
Jul 2019 — Jan 2021 [monthly]
Recruiting NA
First recorded
Mar 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- University of Southern California
For direct contact, visit the study record on ClinicalTrials.gov .